Regional immunosuppression for corneal transplantation

角膜移植的区域免疫抑制

• 批准号: nhmrc : 375136
• 负责人: Dr Helen Brereton
• 金额: $ 17.89万
• 依托单位: Flinders University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/regional-immunosuppression-corneal-transplantation/96615
• 关键词: Regional; immunosuppression; corneal; transplantation

Blindness exerts major physical, emotional and economic constraints and hardship upon the sufferer. Corneal transplantation is a well-accepted surgical treatment for visual impairment caused by opacification of the cornea, the transparent window at the front of the eye. Corneas for transplantation are retrieved from people who have recently died, after permission has been sought from the donor's family. Unfortunately, a significant proportion of corneal transplants fail because they are recognized as foreign, and undergo rejection by the recipient. Once a corneal graft has failed, it is no longer transparent to light. A number of novel interventions are being developed to reduce the incidence of corneal graft rejection, but at present it is uncertain exactly how these should be delivered to the patient. The research described in this application is designed to discover how therapeutic agents and interventions can best be targeted, to prevent corneal graft rejection. Overcoming an unwanted immune response would improve the outcome of corneal transplantation by as much as thirty percent.

失明对患者造成了重大的身体、情感和经济限制和困难。角膜移植是一种被广泛接受的手术治疗，用于治疗因角膜（眼睛前部的透明窗口）混浊而导致的视力障碍。移植用角膜是在征得捐献者家属的同意后，从最近去世的人身上取回来的。不幸的是，相当大比例的角膜移植失败，因为它们被认为是外来的，并受到受体的排斥。一旦角膜移植失败，它就不再透光。正在开发一些新的干预措施来降低角膜移植排斥反应的发生率，但目前还不确定这些措施应如何提供给患者。本申请中描述的研究旨在发现如何最好地靶向治疗剂和干预措施，以防止角膜移植排斥反应。克服不必要的免疫反应将使角膜移植的结果提高30%。